Angiex

Angiex Leverages Fundamental Biological Mechanisms to Gain Revolutionary Power Over Cancer. The founders of Angiex are world-class scientists and angiogenesis experts who have discovered a nuclear internalization biology that functions in the tumor microenvironment, enabling a new class of drugs: Nuclear Delivery Antibody-Drug Conjugates™ (ND-ADC). Angiex’s Nuclear Delivery Platform™ delivers chemotherapeutic payloads to the nuclei of tumor cells and the endothelial cells of tumor vasculature, offering the potential for drugs with superior efficacy and therapeutic margins for solid cancers. Angiex's lead ND-ADC, AGX101, is expected to enter clinical trials in 2022, with other ND-ADCs in the pipeline currently in the discovery and development stages.